Publications by authors named "Gary Haderski"

Claim this Profile
T
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
Gary J Haderski, Bojidar M Kandar, Craig M Brackett, Ilia M Toshkov, Christopher P Johnson

PLoS One· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Tara A Barone, Catherine A Burkhart, Alfiya Safina, Gary Haderski, Katerina V Gurova

Neuro Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.
Minhyung Kim, Nickolay Neznanov, Chandler D Wilfong, Daria I Fleyshman, Andrei A Purmal, Gary Haderski

Cancer Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.
Daniel R Carter, Jayne Murray, Belamy B Cheung, Laura Gamble, Jessica Koach, Gary Haderski

Sci Transl Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
Lyudmila G Burdelya, Craig M Brackett, Bojidar Kojouharov, Ilya I Gitlin, Katerina I Leonova, Gary J Haderski

Proc Natl Acad Sci U S A· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis